HER2 overexpression occurs in about 12–23% of G/GEJ adenocarcinomas, MSI-high/MMR deficiency in about 8–11%, and high PD-L1 expression in 60% [13,16,17]. The gene discussed is ERBB2; the disease is adenocarcinoma.